Champions Oncology (CSBR) Fundamental Analysis: Revenue, Earnings & Valuation

8.66 / 10

Outperform

Fundamental analysis rates CSBR as Outperform with an 8.7/10 strength. Key bullish factors include high interest coverage, robust revenue‑to‑market‑value and solid inventory turnover. Concerns are elevated current‑liabilities ratio and long‑term debt, yet overall outlook remains very promising.

Analysis Checks(7/10)

Revenue-MV

Value-0.46

Score3/3

Weight45.90%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value13.54

Score2/3

Weight0.63%

1M Return0.13%

Inventory turnover ratio

Value103.94

Score2/3

Weight-5.23%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value83.48

Score1/3

Weight-7.32%

1M Return-1.69%

PB-ROE

Value1.89

Score0/3

Weight15.46%

1M Return2.74%

Long-term debt to working capital ratio (%)

Value6.39

Score0/3

Weight-19.94%

1M Return-4.75%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-5.32%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value13.54

Score2/3

Weight0.26%

1M Return0.05%

Cost of sales ratio (%)

Value49.85

Score2/3

Weight-5.03%

1M Return-1.13%

Asset-MV

Value-1.90

Score3/3

Weight80.60%

1M Return11.61%

Is CSBR fundamentally strong?

CSBR scores 8.66/10 on fundamentals and holds a Discounted valuation at present. Backed by its -12.47% ROE, -4.04% net margin, -34.20 P/E ratio, 18.30 P/B ratio, and -138.30% earnings growth, these metrics solidify its Outperform investment rating.